News & Updates

Pooled analyses of the phase III THRIVEAA1 and THRIVE-AA2 trials underpin the potential of the selective oral JAK* 1/2 inhibitor deuruxolitinib to effectively and safely reverse hair loss in adults with moderate-to-severe alopecia areata (AA).

Antenatal exposure to corticosteroids, particularly betamethasone, does not increase the prevalence of cardiovascular risk factors or the incidence of major adverse cardiovascular events (MACE) up to 50 years of age, suggests a study.

Individuals dealing with the stubborn scars and hyperpigmentation left behind by acne may find benefit in trifarotene cream – the newest among the new generation of topical retinoids approved for acne treatment, according to the findings of two vehicle-controlled, phase IV studies presented at AAD 2024.